Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - Canadian Cardiovascular Congress 2009
Evolution in Antiplatelet Therapy in ACS
Edmonton, Alberta / October 24-28, 2009
Edmonton - Relative to standard antiplatelet therapy with clopidogrel, two new agents have been associated with large relative reductions in the risk of thrombotic events in patients with an acute coronary syndrome (ACS). Although...
PRIORITY PRESS - Canadian Cardiovascular Congress 2009
Regional Case Studies with Global Implications: An Exciting Future
Edmonton, Alberta / October 24-28, 2009
Edmonton - It is perhaps fitting that one of the last accredited symposia held at this year’s CCC was one of the most unusual. Firstly, internationally renowned faculty addressed important elemental technologies and systems that are either...
PRIORITY PRESS - Canadian Cardiovascular Congress 2009
Corroborative Data from Registries and Controlled Trials: An ENDEAVOR Analysis
Edmonton, Alberta / October 24-28, 2009
Edmonton - Unlike randomized, controlled trial (RCT) data, registries can serve as a tool by which physicians may gauge their own performance on patients managed in everyday clinical settings. Observations from registries therefore provide...
PRIORITY PRESS - Canadian Cardiovascular Congress 2009
Novel Strategies for Meeting LDL-C Targets in 2009 Canadian Cholesterol Guidelines
Edmonton, Alberta / October 24-28, 2009
Edmonton - The 2009 Canadian Cholesterol Guidelines have set new aggressive targets for LDL-C that are identical for moderate and high-risk patients. For the first time, the guidelines also identify apolipoprotein B as a primary alternative...
PRIORITY PRESS - Canadian Cardiovascular Congress 2009
At the Threshold of Individualized Antiplatelet Therapy in ACS
Edmonton, Alberta / October 24-28, 2009
Edmonton - The current dual antiplatelet standard of ASA/clopidogrel is likely to be displaced by individualized therapy in the acute and long-term management of acute coronary syndromes (ACS). Clopidogrel may still have a role in...
PRIORITY PRESS - 20th World Diabetes Congress (IDF 2009)
The Role of Combination Therapies in Early, Intensive Treatment of Type 2 Diabetes
Montreal, Quebec / October 18-22, 2009
Montreal - Evidence-based guidelines for the management of type 2 diabetes support the achievement and maintenance of A1C <7% to minimize the risk of complications. Speakers here this week emphasized the importance of appropriately...
MEDICAL FRONTIERS - Transcatheter Cardiovascular Therapeutics 2009 Congress
Rapid Evolution Underway in Defining Optimal Antiplatelet Therapy for Patients with Acute Coronary Syndromes
San Francisco, California / September 22-25, 2009
There is a vast amount of new data certain to redefine optimal antiplatelet strategies for acute coronary syndromes (ACS) in upcoming guidelines. All of the newer strategies, including double-the-dose clopidogrel, the newer thienopyridine...
MEDICAL FRONTIERS - 31st Annual Congress of the European Society of Cardiology
Reaching Aggressive Lipid Targets in High-risk Cardiovascular Patients
Barcelona, Spain / August 29-September 2, 2009
Barcelona - Cardiovascular (CV) mortality rates have been decreasing in recent decades, thanks in part to primary and secondary prevention strategies that target risk factors such as obesity, smoking, sedentary lifestyle, hypertension and...
MEDICAL FRONTIERS - 31st Annual Congress of the European Society of Cardiology
Redefining Optimal Anticoagulant Therapy in Patients with Acute Coronary Syndrome
Barcelona, Spain / August 29-September 2, 2009
Barcelona - Newly completed clinical trials with antiplatelet therapies may alter how thrombotic events are prevented in acute coronary syndromes. In two trials, a reduction in thrombotic events was achieved without increasing risk of major...